Fig. 8: β-Glucan-driven protection against IAV is dependent on trained neutrophils.
From: β-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus
a, Schematic of neutrophil depletion experiment using anti-Ly6G antibodies. Mice were infected with IAV (lethal dose) at day 7 post-β-glucan treatment. Anti-Ly6G antibody or isotype control (IC) was administered (i.p.) on day 1 before infection and daily until day 7. b,c, Weight loss (b) and survival (c) monitored over time (n = 10). d, Schematic of adoptive transfer experiment. Neutrophils were isolated from CD45.1 control or β-glucan donor mice and adoptively transferred into naive CD45.2 recipient mice, which were infected with a lethal dose of IAV. e,f, Weight loss (e) and survival (f) monitored over time (n = 10). g, IFNARflox × Mrp8Cre mice were infected with IAV (lethal dose) at day 7 post-β-glucan. h,i, Weight loss (h) and survival (i) monitored over time (n = 8). Data are represented as mean ± s.e.m. Data were analyzed using two-way ANOVA followed by Šidák’s multiple-comparison tests (b, e and h). Survival was monitored by a log(rank) test (c, f and i). *P < 0.05, **P < 0.01. Illustrations in a, d, g created using BioRender.com.
